Clinical Impact of Dyspnea after Ticagrelor Treatment and the Effect of Switching to Clopidogrel in Patients with Myocardial Infarction.
Sang Hyun KimSanghoon ShinEun-Ho ChooIk Jun ChoiSungmin LimDonggyu MoonChan Joon KimMahn-Won ParkMin Chul KimByung-Hee HwangKwan Yong LeeYun Seok ChoiHee-Yeol KimKi-Dong YooDoo Soo JeonYoungkeun AhnKiyuk Changnull nullPublished in: Thrombosis and haemostasis (2024)
Dyspnea is a common side effect among ticagrelor-based DAPTs in AMI patients. Switching from ticagrelor to clopidogrel after 1 month in AMI patients may provide a reasonable option to alleviate subsequent dyspnea in ticagrelor-relevant dyspneic patients, without increasing the risk of ischemic events (NCT02018055).
Keyphrases
- acute coronary syndrome
- end stage renal disease
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- antiplatelet therapy
- chronic kidney disease
- acute myocardial infarction
- prognostic factors
- peritoneal dialysis
- st elevation myocardial infarction
- patient reported outcomes
- oxidative stress
- replacement therapy
- cerebral ischemia